International Journal of Drug Delivery Technology
Volume 14, Issue 4

QbD Based Formulation Development of Delayed-Release Beads for Better Management of Nocturnal Asthma

Vijaykumar V1, Ismail Y1*, Ubaidulla U1, Pradeep K2

1Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, GST Road, Vandalur, Chennai-600048, Tamil Nadu, India.

2Faculty of Health Sciences, Villa college, Male, Maldives 

Received: 23rd Sep 2024; Revised: 8th Oct, 2024; Accepted: 22nd Nov, 2024; Available Online: 25th Dec, 2024

ABSTRACT

The present study discusses about the quality by design (QbD) based formulation development and characterization of delayed release beads for better management of Nocturnal Asthma. Ionotropic gelation technique was used to create Budisonide-loaded pectin-alginate beads, and calcium chloride was added as a crosslinking agent. The central composite design model was used to optimize the beads. The response of beads was 91.9861 % for loading efficiency, 0.998 mm for bead size, and 360 min for time required for 90% drug release. The optimal formulation variables for a formulation were found to be 4.14 mg of pectin, 1.82 mg of alginate, 14.36% of CaCl2, and 5.99 hours of cross-linking time. PEC-ALG beads showed no release in 0.1 N HCl (pH 1.2). In contrast, increased Ca2+ and Na+ ion exchange as well as solvent penetration into the pectin-alginate network have been linked to the quick release from cross-linked beads in phosphate buffer pH 7.4. FTIR results showed that there was no interaction between the medication and the polymers, as evidenced by the significant peaks of BUD detected in the beads. An in vitro study of the toxicity of beads on A549 cell lines revealed significantly higher cell viability than the group of cells treated with pure BUD.BUD loaded PEC-ALG beads could have potential for chrono modulated delivery system for targeting nocturnal asthma.

Keywords: Chronotherapy; Delayed Release Beads; Quality by design; Nocturnal Asthma.

How to cite this article: Vijaykumar V, Ismail Y, Ubaidulla U, Pradeep K. QbD Based Formulation Development of Delayed-Release Beads for Better Management of Nocturnal Asthma. International Journal of Drug Delivery Technology. 2024;14(4):2120-29. doi: 10.25258/ijddt.14.4.25

REFERENCES

  1. Singh, H. N., Saxena, S., Singh, S., & Yadav, A. K. (2013). Pulsatile drug delivery system: Drugs used in the pulsatile formulations. Research Journal of Pharmaceutical Dosage Forms and Technology, 5(3), 115-121.
  2. Kaur, M., & Bala, R. (2013). Chronotherapy: A International Journal of Pharmaceutical Sciences and Research, 4(1), 90.
  3. Tamilanban, T., Mohamedm ajeed, A., & Chitra, V. (2020). Overview of chronopharmacology. Research Journal of Pharmacy and Technology, 13(9), 4457-
  4. Anusha, V., Umashankar, M. S., & Kumar, Y. G. (2023). Pulsatile drug delivery system—an innovative method to treat chronotherapeutic diseases by synchronizing drug delivery with circadian Journal of Applied Pharmaceutical Science, 13(12), 066-078.
  5. Ashwini, D., Asif, K., Ramana, M. V., Mitul, P., & Omkar, D. (2011). Chronotherapy: A novel drug delivery system. International journal of research in Ayurveda & Pharmacy, 2(6), 1692-700.
  6. Awasthi, R., Kumar, P., & Pawar, V. K. (2010). Chronotherapy: science and technology of drug scheduling on  the  basis  of  biological rhythm. JChrDD, 1(1), 9-18.
  7. Bechtold, D. A., Gibbs, J. E., & Loudon, A. S. (2010). Circadian dysfunction in disease. Trends in pharmacological sciences, 31(5), 191-198.
  8. Bhat, B. B., Mehta, C. H., Suresh, A., Velagacherla, , & Nayak, U. Y. (2023). Controlled Release Technologies for Chronotherapy: Current Status and Future Perspectives. Current Pharmaceutical Design, 29(14), 1069-1091.
  9. Bhavani, D., Vani, C. H. S. V., & Rao, V. U. M. (2015). Formulation and evaluation of montelukast sodium pulsatile drug delivery system by core in cup method. Pharmacy Review & Research, 5, 15-23.
  10. Kadam, V. D., & Gattani, S. G. (2010). Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma. Drug delivery, 17(5), 343-351.
  11. Manjunath, G., & Nirmala, S. (2023). Chronomodulated drug delivery: Challenges, benefits, and future directions in asthma treatment. Intelligent Pharmacy.
  12. Kumar Dash, , Kumar Sahoo, R., Padhan, A., Khan,S., Karna, N., Nanda, N., & Dash, S. (2022). Pulsatile Drug Delivery System (PDDS): A Chronotherapeutic Approach for   OptimumTherapy. Journal of Pharmaceutical Research International, 34(31B), 28-45.
  13. Murata, Y., Miyamoto, E., & Kawashima, S. (1996). Additive effect of chondroitin sulfate and chitosan on drug release from calcium-induced alginate gel beads. Journal of controlled release, 38(2-3), 101-108.
  14. Njoku C, K. Otisi S. Application of Central Composite Design with Design Expert v13 in Process Optimization [Internet]. Response Surface Methodology - Research Advances and Applications. IntechOpen; 2023.
  15. Akhtar M, Zaman M, Siddiqi AZ, Ali H, Khan R, Alvi MN, et al. Response Surface Methodology (RSM) approach to formulate and optimize the bilayer combination tablet of Tamsulosin and Finasteride. Saudi Pharm J [Internet]. 2024;32(3):101957.
  16. Abourehab MAS, Rajendran RR, Singh A, Pramanik S, Shrivastav P, Ansari MJ, et al. Alginate as a promising biopolymer in drug delivery and wound healing: A review of the state-of-the-art. Int J Mol Sci [Internet]. 2022;23(16):9035.
  17. Bothun GD. Hydrophobic silver nanoparticles trapped in lipid bilayers: Size distribution, bilayer phase behavior, and optical properties. J Nanobiotechnology [Internet]. 2008;6(1):13.
  18. El-Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci [Internet]. 2009;98(8):2731–46.
  19. Jawed, S., & Cs, S. (2022). Exploration of parteck® SRP 80 and hypromellose for chronomodulated release of LTD4 receptor antagonist and statistical optimization using Central composite design. AAPS PharmSciTech, 23(7), 263.
  20. Raina, B., Sharma, S., Bajwa, P. S., & Sharma, A. R. (2023). Design development and optimization of chronotherapeutic delivery system                                        of Journal              of            Pharmaceutical Innovation, 18(1), 68-78.
  21. Bussemer, T., Peppas, N. A., &Bodmeier, R. (2003). Evaluation of the swelling, hydration and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system. European journal of pharmaceutics and biopharmaceutics, 56(2), 261-270.
  22. Dashevsky, A., & Mohamad, A. (2006). Development of pulsatile multiparticulate drug delivery system coated with aqueous  dispersion  Aquacoat® International journal of pharmaceutics, 318(1- 2), 124-131.
  23. Dhalleine, C., Assifaoui, A., Moulari, B., Pellequer, , Cayot, P., Lamprecht, A., &Chambin, O. (2011). Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery. International journal of pharmaceutics, 414(1-2), 28-34.
  24. Jawed, S., & Satish, C. S. (2023). IVIVC assessment, pharmacokinetic evaluation, and X-ray radiography mapping of Novel Parteck® SRP 80 and hypromellose-loaded LTD4 receptor  antagonistchronosystem. Future Journal of Pharmaceutical Sciences, 9(1), 105.
  25. Jeganath, S., & Senthilkumaran, K. (2014). Formulation development and in vitro evaluation of pulsatile release tablet of World Journal of Pharmaceutical Research, 4(1), 1197-1208.
  26. Khan, , Patil, K., Bobade, N., Yeole, P., & Gaikwad,(2010). Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropiniroleand evaluation of brain targeting efficiency in rats. Journal of drug targeting, 18(3), 223-234.
  27. Krishnaveni, B., Muthukumaran, M., & Krishnamoorthy, B. (2013). Development and evaluation of pulsatile drugs delivery system containing montelukast sodium by press coated tablet using natural polyssacharides. Int J Adv Pharm Gen Res, 1(2), 41-51